

**Supplementary information for**


**LncRNA CTBP1-DT-encoded microprotein DDUP sustains DNA damage response signalling to  
trigger dual DNA repair mechanisms**

Ruyuan Yu <sup>1,2, §</sup>, Yameng Hu <sup>1,2, §</sup>, Shuxia Zhang <sup>1,2, §</sup>, Xincheng Li <sup>1,2</sup>, Miaoling Tang <sup>1,2</sup>, Meisongzhu  
Yang <sup>1,2</sup>, Xingui Wu <sup>1,2</sup>, Ziwen Li <sup>1,2</sup>, Xinyi Liao <sup>1,2</sup>, Yingru Xu <sup>1,2</sup>, Man Li <sup>1,2</sup>, Suwen Chen <sup>1,2</sup>, Wanying  
Qian<sup>1,2</sup>, Li-Yun Gong<sup>4</sup>, Libing Song<sup>3</sup>, Jun Li <sup>1,2, \*</sup>

**Correspondence to:** Jun Li

E-mail: [lijun37@mail.sysu.edu.cn](mailto:lijun37@mail.sysu.edu.cn)

Supplementary Figure S1




**Supplementary Figure S1. LncRNA CTBP1-DT-encoded DDUP microprotein promotes DNA damage repair.** **A.** Diagram of the 5'- and 3'-untranslated regions (UTRs) and the open reading frame (ORF) in human lncRNA CTBP1-DT (upper) and the corresponding 186 amino acid (aa) sequence (lower). **B.** Real-time PCR analysis of CTBP1-DT expression in sh-vector- and CTBP1-DT shRNA-transduced cells. GAPDH served as a control. **C.** Real-time PCR analysis of CTBP1-DT expression in


the indicated cells treated with CPT (10  $\mu$ M) or VP-16 (10  $\mu$ M) or CDDP (5  $\mu$ M) for 1 hour or with IR (10 Gy) and were allowed to recover for six hours. GAPDH served as a loading control. **D.** Representative images (left) and quantification (right) of damaged DNA in the indicated vehicle-treated cells determined by comet assay ( $n = 100$ ). Scale bar = 20  $\mu$ m. **E.** Representative images (left) and quantification (right) of  $\gamma$ -H2AX foci in the indicated cells with vehicle treatment. At least 100 cells were counted. Scale bar = 5  $\mu$ m. **F.** Representative images (left) and quantification (right) of  $\gamma$ -H2AX foci in the indicated cells treated with CPT (10  $\mu$ M), VP-16 (10  $\mu$ M), CDDP (5  $\mu$ M) for 1 hour or IR (10 Gy) (>100 counted cells). Scale bar = 5  $\mu$ m. **G-H.** MTT assay analysis of indicated cell survival in response to vehicle (G) or CPT(H) treatment at the indicated concentration. Each error bar represents the mean  $\pm$  SD of three independent experiments (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ).

Supplementary Figure S2


A




B




C




D



E



F




Supplementary Figure S2 Microprotein DDUP, but not CTBP1-DT RNA, promotes DNA damage repair.

**A.** Quantification of  $\gamma$ -H2AX foci in the indicated cells treated with CPT (10  $\mu$ M), VP-16 (10  $\mu$ M), CDDP (5  $\mu$ M) for 1 hour, or IR (10 Gy) (>100 counted cells). **B.** MTT assay analysis of indicated cell survival in response to CPT treatment at the indicated concentration. **C.** Mutagenesis of target sites revealed by the presence of a PCR product with 300 bp digestion products in T7 endonuclease 1 (T7E1) assays in HeLa/DDUP<sup>-/-</sup>#1 and DDUP<sup>-/-</sup>#2 cells. **D.** Genomic DNA sequence analysis showing that


homozygous DDUP deletion occurred downstream of the neighbouring start codon (ATG) in HeLa/DDUP<sup>-/-</sup>-#1 and DDUP<sup>-/-</sup>-#2 cells. **E.** MTT assay analysis of the survival of control and DDUP-KO cells in response to CPT treatment at the indicated concentration. **F.** Representative images (upper) and quantification (lower) of the colony formation ability of the indicated cells treated with CPT (10  $\mu$ M) or CDDP (5  $\mu$ M), as determined by a colony-formation assay. Each error bar represents the mean  $\pm$  SD of three independent experiments (\* $p$  < 0.05, \*\* $p$  < 0.01, \*\*\* $p$  < 0.001).

### Supplementary Figure S3



**Supplementary Figure S3. The IRES in the 5'UTR of CTBP1-DT is essential for DNA damage-induced DDUP translation.** **A.** Upper: Diagram of uORFs, putative IRES and DDUP-coding regions in CTBP1-DT RNA. Lower: IRESfinder was used to predict the potential IRES region in the 5'UTR of CTBP1-DT RNA. **B.** Quantification of  $\gamma$ -H2AX foci in HeLa cells with CPT (10  $\mu$ M, 1h) (>100 counted cells). **C.** Quantification of damaged DNA in the indicated cells with CPT (10  $\mu$ M, 1h) analyzed by comet assay ( $n = 100$ ). Each error bar represents the mean  $\pm$  SD of three independent experiments (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ).

Supplementary Figure S4




**Supplementary Figure S4. Phosphorylation of DDUP is essential for DDUP-mediated damage repair.** **A.** IF staining using anti-DDUP antibody in vehicle-, or CPT (10  $\mu$ M)-, or VP-16 (10  $\mu$ M)-treated control and DDUP-KO HeLa cells. **B.** IF staining of ATR foci in vehicle- and CPT (10  $\mu$ M, 1h)-treated DDUP-KO HeLa cells. **C.** Molecular docking between ATR and DDUP performed using the Cluspro 2.0 web server (<https://cluspro.org/help.php>) shown in cartoon representation. **D.** Co-IP assay analysis of the DDUP-interacting region in ATR using anti-ATR antibody in CPT-treated (10  $\mu$ M, 1h) 293T cells transfected with full-length or truncated ATR fragments (right). **E.** Representative images (left) and quantification (right) of damaged DNA in the indicated cells analysed by comet assay ( $n = 100$ ). The indicated cells were pre-treated with or without berzosertib (80 nM) for 1 hour, and then treated with CPT (10  $\mu$ M) for 1 hour. Each error bar represents the mean  $\pm$  SD of three independent experiments ( $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ).




Supplementary Figure S5


A




B



C



D



**Supplementary Figure S5. Phosphorylated DDUP forms a complex with γ-H2AX and RAD18. A.**


IF staining analysis of the expression of the indicated truncated DDUP protein in CPT (10 μM, 1h)-treated HeLa cells. **B.** Chromatin fraction and IB analysis of expression of DDUP/WT, DDUP/N, DDUP/M, DDUP/ΔC, and DDUP/C in chromatin in CPT (10 μM, 1h)-treated 293T cells. H3 served as a loading control. **C.** IB analysis of DNA-bound endogenous DDUP expression in chromatin fraction (upper) and whole cell lysates (lower) extracted from CPT (10 μM, 1h)-treated 293T cells transfected with DDUP/N, DDUP/ΔC or DDUP/C. H3 served as a loading control for chromatin fractions and GAPDH served as a loading control for whole cell lysates. **D.** Co-IP assay analyses of the DDUP/γ-H2AX interaction in CPT (10 μM, 1h)-treated 293T cells transfected with Flag-tagged DDUP/N (0, 0.5, 1.0, 5.0 μg), the




DDUP/RAD18 interaction in CPT (10  $\mu$ M, 1h)-treated 293T cells transfected with Flag-tagged DDUP/ $\Delta$ C (0, 0.5, 1.0, 5.0  $\mu$ g), and formation of the DDUP/ $\gamma$ -H2AX/RAD18 complex in CPT (10  $\mu$ M, 1h)-treated 293T cells transfected with Flag-tagged DDUP/C (0, 0.5, 1.0, 5.0  $\mu$ g). The detailed technical information was described in the Material and Methods section.

Supplementary Figure S6


A




B




C




D



E




F



**Supplementary Figure S6. DDUP enhances the retention of RAD18 at DNA damage sites. A.** IF quantification of RPA2-foci using anti-RPA2 antibody (left) and RAD51-foci using anti-RAD51 antibody (right) in the indicated cells treated with CPT (10  $\mu$ M, 1h). **B.** IB analysis of RAD18 expression in scramble- and RAD18 siRNAs-transfected HeLa/DDUP cells. GAPDH served as a loading control. **C.** Quantification of  $\gamma$ -H2AX foci determined by IF staining using anti- $\gamma$ -H2AX antibody in the indicated cells treated with CPT (10  $\mu$ M, 1h). **D.** Percentage of GFP+ and mCherry+ cells, gated on BFP+, of three biological replicates. **E.** IB analysis of expression of DNA-bound and total monoubiquitinated

PCNA and DDUP in the indicated DDUP-KO HeLa cells treated with CDDP (5  $\mu$ M, 1h) or UV radiation (60 J/m<sup>2</sup>). H3 and  $\alpha$ -Tubulin served as a loading control. **F.** Representative images (left) and time course (right) of the formation of PCNA foci in untreated or CDDP (5  $\mu$ M)- or UV radiation (60 J/m<sup>2</sup>)-treated control and DDUP-KO HeLa cells, and allowed to recover for the indicated times. Each error bar represents the mean  $\pm$  SD of three independent experiments (\* $p$  < 0.05, \*\* $p$  < 0.01, \*\*\* $p$  < 0.001).

## Supplementary Figure S7



### Supplementary Figure S7. Upregulation of DDUP confers resistance to cisplatin in ovarian

**cancer cells *in vitro*.** **A-B.** IB analysis of DDUP expression in Vector- or DDUP-transduced PDOVCs #1 and #2 (**A**) or sh-vector- or DDUP shRNA(s)-transduced PDOVCs #3 and #4 (**B**). GAPDH served as a loading control. **C.** Representative images (left) and quantification (right) of damaged DNA in the indicated cells analysed by comet assay ( $n = 100$ ). The indicated cells treated with CDDP(5  $\mu$ M) for 1 hour. Scale bar = 5  $\mu$ m. Each error bar represents the mean  $\pm$  SD of three independent experiments (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ).

## Supplementary Tables

**Supplementary Table 1. Label-free quantitative (LFQ) mass spectrometry analysis of the potential DDUP-interacting proteins in CPT- vs. Vehicle-treated cells**

Accessions	Gene name	Vehicle _rep1	Vehicle _rep2	CPT_ rep1	CPT_ rep2	Log2 FC	P value
sp Q13535 ATR_HUMAN	ATR	NA	NA	24.99	24.67	4.81	7.25E-06
sp Q9NS91 RAD18_HUMAN	RAD18	NA	NA	24.30	24.51	4.12	7.12E-05
sp O43502 RAD51C_HUMAN	RAD51C	NA	NA	24.30	24.50	4.12	7.12E-05
sp Q00839 HNRPU_HUMAN	HNRNPU	20.26	20.81	24.02	23.95	3.45	8.03E-05
sp P62805 H4_HUMAN	H4C1	22.25	21.84	24.76	24.96	2.82	1.34E-04
sp P06748 NPM1_HUMAN	NPM1	23.50	23.81	26.41	26.41	2.75	8.17E-05
sp P23527 H2B1O_HUMAN	H2BC17	22.67	22.92	25.49	25.49	2.64	8.38E-05
NR_033339.1 DDUP	DDUP	NA	NA	22.89	22.83	2.61	1.16E-04
sp P16104 H2AX_HUMAN	H2AX	NA	NA	22.04	22.42	2.46	2.09E-04
sp P78347 GTF2I_HUMAN	GTF2I	NA	NA	22.61	22.42	2.18	2.75E-04
sp P11940 PABP1_HUMAN	PABPC1	23.34	23.20	25.20	25.5	2.08	3.03E-04
sp Q9Y2X3 NOP58_HUMAN	NOP58	25.92	25.92	28.11	27.98	2.02	2.42E-04

**Supplementary Table 2. Primers and Oligonucleotides used in this study**

<b>Primer used for qPCR</b>	
CTBP1-DT-up	5'-CCATCCTCTGCAGCAAGTCA -3'
CTBP1-DT-dn	5'-CTCCGTTCTCAGTTGCCTGT-3'
GAPDH-up	5'-GGAGCGAGATCCCTCCAAAAT -3'
GAPDH-dn	5'-GGCTGTTGTCATACTTCTCATGG-3'
<b>Primer used for subcloning and plasmid construction</b>	
CTBP1-DT-up	5'-GCCGCCACGTCAGCGCCTG-3'
CTBP1-DT-dn	5'-TGGCAGTTTTTCAGCGATTGT-3'
DDUP-Flag-up	5'-gtgtcgtgaggattgggatccgccATGTGGTTGGTGGAGTGCACA-3'
DDUP-Flag-dn	5'-gaagaattcgtccgggatccTCACTTATCGTCGTCATCCTTGTAAATC TGATAACGCGCTGACAAGC-3'
ATG1mDDUP-up	5'-GGGACGATtTGGTTGGTGGAGTGCACAGGCAG-3'
ATG1mDDUP-dn	5'-ACCAACCAaATCGTCCCTTCCCGGCAGCCTCA-3'
ATG2mDDUP-up	5'-CTCAGCATtGACAGGCAGCCAGGAGAAGGCA-3'
ATG2mDDUP-dn	5'-TGCCTGTCaATGCTGAGCAGACAGGAAAGTCC-3'
DDUP/T174A-up	5'-CGTCTACgCACAGTGTTCTGTCTGCACAGCTTG-3'
DDUP/T174A-dn	5'-AACACTGTGcGTAGACGGAGGCCATGGAGAGT-3'
DDUP/T174D-up	5'-CGTCTACgacCAGTGTTCTGTCTGCACAGCTTG-3'
DDUP/T174D-dn	5'-AACACTGgtcGTAGACGGAGGCCATGGAGAGT-3'
Flag-DDUP/N-up	5'-gtgtcgtgaggattgggatccgccATGGATTACAAGGATGACGACGATAAG TGGTTGGTGGAGTGCACA-3'
Flag-DDUP/N-dn	5'-gaagaattcgtccgggatccTCAATCACAACCTGACTTGCTGC-3'
Flag-DDUP/ΔC-up	5'-gtgtcgtgaggattgggatccgccATGGATTACAAGGATGACGACGATAAG TGGTTGGTGGAGTGCACA-3'
Flag-DDUP/ΔC-dn	5'-gaagaattcgtccgggatccTCAGGAGAGGAACTGTTCTTCTGG-3'
Flag-DDUP/C-up	5'-gtgtcgtgaggattgggatccgccATGGATTACAAGGATGACGACGATAAG AGGATCCACTTCCTGCGC-3'
Flag-DDUP/C-dn	5'-gaagaattcgtccgggatccTCATGATAACGCGCTGACAAGC-3'

<b>Primer used for CRISPR Cas9 System</b>	
gRNA#1	5'-GGTTGGTGGAGTGCACAGGCAGG-3'
gRNA#2	5'-TGCACAGGCAGGGACCTCACTGG-3'
CTBP1-DT-up	5'-TTATTAGTCGGTGTGTTCACTATC-3'
CTBP1-DT-dn	5'-AGCAGAGGGTAGAATGGTGTT-3'
<b>shRNA</b>	
ShRNA#1_CTBP1 -DT	5'-ACCTCGGAATGATGCAGACTCCTATCTCAAGAGGATAGGAGTCTGCA TCATTCCTT-3'
ShRNA#2_CTBP1 -DT	5'-ACCTCGTTCGTCTGCACAGCTTGTCATCAAGAGTGACAAGCTGTGC AGACGAACTT-3'
<b>siRNA</b>	
Si RAD18#1	5'-GACCAAAGAGACACGTTCTGT-3'
Si RAD18#2	5'-GCTGTTTATCACGCGAAGAGA-3'
Si DDUP#1	5'-GGAAUGAUGCAGACUCCUAUC-3'
Si DDUP#2	5'-GTTTCGTCTGCACAGCTTGTC-3'
Si H2AX#1	5'-TGGACTAATTTTATTAAAGGATT-3'
Si H2AX#2	5'-GACTAATTTTATTAAAGGATTGT-3'



**Supplementary Table 3. Clinicopathological characteristics of clinical samples and expression of DDUP in platinum-treated Ovarian Cancer**

Characteristics	No. patients	DDUP expression		P value
		Low (n=217)	High (n=150)	
<b>Age (years)</b>				
≤ 62	192	109	83	0.336
> 62	175	108	67	
<b>Histological type</b>				
Serous	270	158	112	0.378
Endometrioid	43	26	17	
Mucinous	23	11	12	
Undifferentiated	31	22	9	
<b>FIGO stage</b>				
I /II	89	61	28	0.038
III/IV	278	156	122	
<b>Histologic grade</b>				
1	31	15	16	0.101
2	75	34	41	
3	261	168	93	
<b>Chemo-response status</b>				
Chemoresistance	190	60	130	<0.001
Chemosensitivity	177	157	20	
<b>Recurrence</b>				
Yes	248	111	137	<0.001
No	119	106	13	
<b>Vital status</b>				
Alive	143	112	31	<0.001
Dead	224	105	119	

**Supplementary Table 4. Univariate and multivariate analysis of different prognostic parameters in patients with ovarian cancer by Cox-regression analysis.**

	Univariate analysis		Multivariate analysis	
	<i>P</i>	Hazard ratio (95% CI)	<i>P</i>	Hazard ratio (95% CI)
Age (years)	0.137	0.819 (0.629-1.065)		
Histological type	0.002	0.773(0.659-0.907)	0.006	0.776 (0.648-0.929)
Histologic grade	< 0.001	0.673 (0.547-0.829)	0.007	0.734 (0.585-0.920)
FIGO stage	0.001	1.847 (1.267-2.691)	0.013	1.664 (1.111-2.491)
Recurrence	< 0.001	3.068 (2.170-4.336)	< 0.001	2.479 (1.545-3.978)
Chemo-response status	< 0.001	2.171 (1.642-2.869)	0.009	0.548 (0.349-0.861)
DDUP expression	< 0.001	3.157 (2.401-4.152)	< 0.001	2.797 (1.974-3.963)